Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

17. Oktober 2024 07:01 ET | Quelle: Travere Therapeutics, Inc.

Travere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy

Travere Therapeutics and CSL Vifor announce swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA nephropathy.
07. September 2023 04:25 ET | Quelle: Curium

Curium Announces Exclusive Distribution Agreement in Switzerland with b.e. Imaging for PYLCLARI™, an Innovative 18F-PSMA Pet Tracer Indicated in Adults with Prostate Cancer

PARIS, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that it has entered into an exclusive rights agreement with b.e. Imaging, for the distribution...
16. Dezember 2020 03:00 ET | Quelle: Esperion Therapeutics, Inc.

First-in-class cholesterol-lowering treatment NILEMDO® * (bempedoic acid) tablet and its combination with ezetimibe NUSTENDI® * (bempedoic acid and ezetimibe) tablet approved in Switzerland

- NILEMDO® (bempedoic acid) is the first oral, once-daily treatment approved in almost two decades to lower low-density lipoprotein cholesterol (LDL-C) for indicated patients - - Bempedoic acid and...